secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACADIA PHARMACEUTICALS INC (ACAD)
CIK:        0001070494
Form:       8-K
Filed at:   2023-08-02T23:59:59+00:00
Accession:  0000950170-23-037216
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acadia Q2 net income $1.1M; DAYBUE launch strong with $23.2M sales; guides Q3 DAYBUE $45-55M
--------------------------------------------------------------------------------

- Q2 net income of $1.1M ($0.01/share) vs net loss of $34.0M in prior year; total product sales $165.2M.
- DAYBUE (trofinetide) first full quarter of sales: $23.2M; expanded licensing deal with Neuren for global rights.
- NUPLAZID Q2 sales $142.0M, +5.5% YoY; full year guidance raised to $530-545M.
- R&D expenses decreased to $58.8M; SG&A increased to $96.0M due to DAYBUE launch costs.
- Appointed Dr. Kevin R. Oliver as SVP, Chief Business Officer; Phase 3 negative symptoms schizophrenia trial enrollment complete, results Q1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070494/000095017023037216/0000950170-23-037216-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070494/000095017023037216/acad-20230802.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-037216

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer